Skin health and disease · 2026
Efficacy and tolerability of rituximab in patients with pemphigus foliaceus: a single-centre retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sadeghinia Ali, Tavasoli Mona, Vafaeian Ahmad, Emadi Seyed Naser, Aryanian Zeinab, Daneshpazhooh Maryam
Аннотация
BACKGROUND: Pemphigus foliaceus (PF), a rare autoimmune blistering disease, still lacks a well-established optimal treatment approach. Rituximab (RTX) is not yet approved by the US Food and Drug Administration for the treatment of PF.
OBJECTIVES: To evaluate the efficacy and tolerability of RTX in treating PF.
METHODS: In this study, all patients diagnosed with PF and treated with RTX and referred to a tertiary hospital over a period of 7 years were included. Clinical outcomes were retrospectively evaluated using Pemphigus Disease Area Index (PDAI) scores and prednisolone dosages at a minimum of four follow-up points. Patients were divided into two groups: newly diagnosed (NDP) and previously treated patients (PTP). Comparative analyses were performed across follow-up visits and study groups.
RESULTS: A total of 96 patients were included. Significant decreases in PDAI scores and prednisolone dosages were observed for all patients (both P < 0.0001), with no significant differences found between the study groups during a 12-month follow-up period. The NDP group exhibited a higher rate of complete remission (P = 0.03) and a shorter time to complete remission (P = 0.006) compared with the PTP group. There were no significant variations in relapse rate and time to relapse among the study groups. The most common treatment-related adverse effects of RTX were those associated with the injection, which could be managed with supportive care.
CONCLUSIONS: RTX emerges as a promising therapeutic option with minimal side effects for the treatment of PF.
OBJECTIVES: To evaluate the efficacy and tolerability of RTX in treating PF.
METHODS: In this study, all patients diagnosed with PF and treated with RTX and referred to a tertiary hospital over a period of 7 years were included. Clinical outcomes were retrospectively evaluated using Pemphigus Disease Area Index (PDAI) scores and prednisolone dosages at a minimum of four follow-up points. Patients were divided into two groups: newly diagnosed (NDP) and previously treated patients (PTP). Comparative analyses were performed across follow-up visits and study groups.
RESULTS: A total of 96 patients were included. Significant decreases in PDAI scores and prednisolone dosages were observed for all patients (both P < 0.0001), with no significant differences found between the study groups during a 12-month follow-up period. The NDP group exhibited a higher rate of complete remission (P = 0.03) and a shorter time to complete remission (P = 0.006) compared with the PTP group. There were no significant variations in relapse rate and time to relapse among the study groups. The most common treatment-related adverse effects of RTX were those associated with the injection, which could be managed with supportive care.
CONCLUSIONS: RTX emerges as a promising therapeutic option with minimal side effects for the treatment of PF.